The Evolving Field of CAR T-Cell Therapy

Interview with Joseph "Burl" and Judy Webnar: The Patient/Caregiver Experience of Receiving CAR T-Cell Therapy

Interview with Tabitha Matthews, MSN, APRN-NP, AGACNP-BC, AOCNP: Risk Evaluation and Mitigation Strategies (REMS) Removal and Impact on Care Delivery

View all

Welcome to the CAR T-Cell Therapy Resource Center! Here you’ll find current information, news items, highlights from the literature, case studies, and other resources that focus on CAR T-cell therapies and the advanced practitioner’s role in delivering high-quality care to our patients. If you have any feedback or questions, please contact jadpro-editor@conexiant.com.

Meredith Beaton, MSN, AGACNP-BC Assistant Professor of Medicine
Associate Vice Chair for APP Development & Mentorship
Medical Director, Inpatient BMT Program
University of Colorado School of Medicine

Chimeric antigen receptor natural killer cell therapy for solid tumors: Mechanisms, clinical progress, and strategies to overcome the tumor microenvironment

CAR T-Cell Therapy Resource Center

The Evolving Field of CAR T-Cell Therapy

American Cancer Society Patient Lodging Programs

ASTCT NucleusPlus: Insights on Emerging CAR-T Therapies

NCCN: Immunotherapy Side Effects - CAR T-Cell Therapy

ASTCT: CAR-T Toxicity Grading and Management

The EBMT/EHA CAR-T Cell Handbook

Blood Advances

CD19 CAR T-cell outcomes in relapsed/refractory extramedullary B-ALL: a multi-site, retrospective cohort review

Journal of Medical Economics

Time to access matters: Patient gains from faster CAR T-cell reimbursement in Europe

British Journal of Clinical Pharmacology

Efficacy, safety and cost-effectiveness of CAR-T therapy

Immunology

Strategies of AI-driven CAR-T cell therapy towards solid tumours

Frontiers in Immunology

Impact of inotuzumab ozogamicin as bridging therapy and tumor burden in CAR-T therapy for B-acute lymphoblastic leukemia

Experimental Biology and Medicine

Chimeric antigen receptor natural killer cell therapy for solid tumors: Mechanisms, clinical progress, and strategies to overcome the tumor microenvironment

Transplantation and Cellular Therapy

Financial toxicity in a phase I/II trial of LV20.19 CAR-T cell for B-cell malignancies a longitudinal, qualitative study

Journal of Medical Cases

Cyclophosphamide for the treatment of refractory immune effector cell-associated neurotoxicity syndrome following CD19-targeted CAR T-cell therapy

Clinical and Translational Oncology

Emerging strategies to reduce the side effects of CAR-T cell therapy: Focusing on gene editing and nanotechnology

World Journal of Oncology

Neurotoxicity of immunotherapy: Immune checkpoint inhibitor-related encephalitis vs. immune effector cell-associated neurotoxicity syndrome

Prophylactic Tocilizumab in Selected High-Risk or Outpatient CAR-T Populations

Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy in a Patient With Multiple Myeloma

Bloodless Medicine Management of a Patient Receiving CAR T-Cell Therapy

Fast Facts #12: BCMA Targets